About: Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
Creator	Achraf, Al Al Faraj, Achraf Faraj, Itani, Rasha Tobaiqy, Mansour
Source	Medline; PMC
abstract	On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.7150/thno.46691
bibo:pmid	32483428
has license	cc-by
sha1sum (hex)	c4d05bd69c7f7de1c3af3d05b87e34cfc3b5d5cb
schema:url	https://doi.org/10.7150/thno.46691
resource representing a document's title	Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
has PubMed Central identifier	PMC7254986
has PubMed identifier	32483428
schema:publication	Theranostics
resource representing a document's body	covid:c4d05bd69c7f7de1c3af3d05b87e34cfc3b5d5cb#body_text
is schema:about of	named entity 'decade' named entity 'addition' named entity 'effective' named entity 'carriers' named entity 'deliver' named entity 'CLINICAL TRIALS' named entity 'GAVE' named entity 'CURRENTLY' named entity 'JANUARY' named entity 'ROLE' named entity '28I' named entity 'DELIVERY SYSTEMS' named entity 'THERAPEUTIC' named entity 'TARGETED' named entity 'NONINVASIVE IMAGING' named entity 'CARRIERS' named entity 'higher' named entity 'targeted' named entity 'fired' named entity 'nanoparticles' named entity 'siRNA' named entity 'While' named entity 'efficiently' named entity 'drugs' named entity 'promising' named entity 'light' named entity 'sites' named entity 'therapeutic agents' named entity 'nanoparticles' named entity 'infectious disease' named entity 'infection' named entity 'imaging modalities' named entity 'theranostic' named entity 'viroids' named entity 'virus' named entity 'vaccine' named entity 'host cells' named entity 'coronaviruses' named entity 'Sunitinib' named entity 'heptad repeat' named entity 'low pH' named entity 'antigenic determinant' named entity 'gene' named entity 'cardiovascular disease' named entity 'complement activation' named entity 'electrostatic attraction' named entity 'RISC' named entity 'targeted therapy' named entity 'therapeutic agents' named entity 'hypertension' named entity 'biocompatible' named entity 'mice' named entity 'siRNA' named entity 'lipids' named entity 'nasal spray' named entity 'influenza' named entity 'Baricitinib' named entity 'influenza' named entity 'antigen' named entity 'HBV' named entity 'SARS' named entity 'cellular membrane' named entity 'MERS' named entity 'iron oxide' named entity 'Chloroquine' named entity 'spike protein' named entity 'COVID-19 disease' named entity 'host cell's' named entity 'SAPN' named entity 'humoral' named entity 'genome' named entity 'epithelial cells' named entity 'coronaviruses' named entity 'vaccination' named entity 'nucleic acids' named entity 'virus' named entity 'liposomes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software